MO HB 2: House Bill 2
House Bill 2 introduces new regulations for AI in healthcare, impacting compliance for health systems and medical device companies.
Aforeworn detected this change in the Healthcare AI Regulation (FDA / ONC) space on August 9, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Health systems, medical device companies, health tech startups, and digital health compliance teams. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Healthcare AI Regulation (FDA / ONC) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New regulatory framework for AI applications in healthcare, including requirements for bias audits and clinical decision support systems.
Who it affects
Health systems, medical device companies, health tech startups, and digital health compliance teams.
What you must do
Review and update compliance protocols to align with the new AI regulations outlined in House Bill 2.
Deadline
Not specified.
Source: https://documents.house.mo.gov/xml/261-HB2.xml
Never miss a change like this again
Aforeworn watches Healthcare AI Regulation (FDA / ONC) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Healthcare AI Regulation (FDA / ONC)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- WI 2025 Assembly Bill 11: Pelvic exams on unconscious patients
- Coalition for Decentralized Healthcare and Life Sciences Recognized by United Nations Global Dialogue on AI Governance - webwire.com
- Abbott gains FDA clearance, CE mark approval for AI-powered imaging platform - cardiovascularbusiness.com
- The AI Tension in Healthcare: Patent Strategy, FDA Reality, and HIPAA Constraints - medcitynews.com